Core Viewpoint - The resignation of the Vice President of Shandong Xinhua Pharmaceutical Co., Ltd. is officially announced, and it is stated that this will not impact the company's normal operations [1] Group 1: Resignation Announcement - The company received a written resignation report from Vice President Zheng Zhonghui on September 5, 2025, due to personal reasons [1] - Zheng Zhonghui will not hold any executive position in the company after his resignation [1] - The resignation is effective immediately upon delivery to the board of directors [1] Group 2: Impact on Company Operations - As of the announcement date, Zheng Zhonghui has no outstanding commitments that he has failed to fulfill [1] - His resignation will not affect the company's normal production and operational activities [1] - There were no disagreements between Zheng Zhonghui and the board during his tenure [1] Group 3: Shareholding Information - Zheng Zhonghui holds 397,550 A shares of the company, and he will continue to manage his shares according to relevant laws and regulations after his resignation [1] - The board expresses gratitude for Zheng Zhonghui's contributions during his tenure [1]

Group 1 - The company will hold a half-year performance briefing on September 23, 2025, from 16:00 to 17:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [1][2] - Investors can submit questions before the event through the Roadshow Center website or via the company's email [1][2] Group 2 - Key participants in the briefing will include the company's Chairman and General Manager Wang Jianjun, independent directors, and other relevant personnel [2] - The company will address common investor concerns during the briefing, adhering to information disclosure regulations [2] - After the briefing, investors can access the main content and details of the event on the Roadshow Center website [2]

Core Viewpoint - China Eastern Airlines Co., Ltd. is set to hold a mid-year performance briefing on September 12, 2025, in collaboration with its subsidiary, Eastern Air Logistics Co., Ltd., to enhance investor understanding of its performance and operations [1][2]. Group 1: Performance Briefing Details - The performance briefing will take place on September 12, 2025, from 11:00 to 12:00 [2][3]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3]. - Investors can submit questions from September 6 to September 11, 2025, via the Roadshow Center website or through email [3]. Group 2: Participants and Contact Information - Key participants in the briefing will include the Chairman, independent directors, and senior management of China Eastern Airlines and Eastern Air Logistics [2]. - Contact information for inquiries includes phone numbers and an email address for investor relations [3]. Group 3: Additional Information - After the briefing, investors can access the main content and details of the event through the Shanghai Stock Exchange Roadshow Center [4]. - The company expresses gratitude for the support and attention from investors [4].

Core Viewpoint - Tasly Pharmaceutical Group Co., Ltd. will participate in the 2025 Tianjin Listed Companies Investor Online Reception Day to enhance interaction with investors [1][2] Group 1 - The event will be held online on September 11, 2025, from 13:00 to 17:30, with a specific interactive session for investors from 15:00 to 17:00 [1][2] - Investors can participate through the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [1] - The company's management, including the General Manager and other key executives, will discuss the 2025 semi-annual performance, corporate governance, development strategy, and operational status [2] Group 2 - Investors are encouraged to submit questions via email by September 10, 2025, and the company will address commonly asked questions during the performance briefing [2]

新疆国际实业股份有限公司 关于聘任董事会秘书的公告 证券代码：000159 证券简称：国际实业 公告编号：2025-46 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 新疆国际实业股份有限公司（以下简称"公司"）于 2025 年 9 月 1 日召开了第九届董事会第八次临时会议，审议通过了《关于聘任 董事会秘书的议案》，现将相关情况公告如下： 一、关于聘任董事会秘书情况 根据公司内部调整，沈永先生辞去董事、董事会秘书、财务总监 职务，辞职后仍在公司担任副总经理职务，为完善公司治理结构，确 保公司规范运作，经董事会提名委员会提名，拟聘任陈昱成先生担任 公司董事会秘书，任期自董事会审议通过之日起至公司第九届董事会 任期届满止。 陈昱成先生已参加深圳证券交易所董事会秘书任职培训并取得 董事会秘书任职培训证明，具备履行董事会秘书职责所必需的专业知 识和工作经验，截至本公告披露日，陈昱成先生未持有公司股票，与 持有公司百分之五以上股份的股东、实际控制人之间不存在关联关系； 与公司其他董事、监事及高级管理人员不存在关联关系。陈昱成先生 不存在《公司法》第一百四十六条、《深圳证 ...

Core Points - The company will hold a half-year performance briefing on September 15, 2025, from 11:00 to 12:00 [1][2] - The briefing will be conducted in a text interaction format, allowing for real-time communication with investors [2][3] - Key company personnel, including the Chairman and President, will participate in the briefing [2] Meeting Details - The meeting will take place at the Shanghai Stock Exchange Roadshow Center [2] - Investors can submit questions from September 8 to September 12, 2025, before 16:00 [3] - The company will address commonly asked questions during the briefing [2][3] Contact Information - Investors can reach the company's Investor Relations Department for inquiries via phone, fax, or email [3]

证券代码：000159 证券简称：国际实业 公告编号：2025-47 新疆国际实业股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 一、独立董事辞职 新疆国际实业股份有限公司（以下简称"公司"）董事会于近日 收到公司独立董事董运彦先生的书面辞职报告。董运彦先生因个人原 因申请辞去公司独立董事职务，同时一并辞去董事会专门委员会相关 职务，辞职后不再担任公司其他任何职务。 新疆国际实业股份有限公司 董 事 会 个人简历： 杨玉青先生，1975 年 7 月出生，汉族，大专，中国国籍，无永 久境外居留权。2011 年 6 月-2016 年 5 月在人民数字科技产业有限公 司任财务负责人；2016 年 6 月-2020 年 5 月在中农联控股有限公司任 财务管理中心负责人；2020 年 6 月-2021 年 5 月在中国供销冷链物流 有限公司任财务部副总经理；2021 年 5 月-2022 年 4 月在雨润控股集 团有限公司任控股财经稽核部负责人兼农产品集团财务总监；2022 年 5 月-2023 年 4 月在北京亿路通行科技有限公司任财务负责人； 2023 年 ...

证券代码：000159 证券简称：国际实业 公告编号：2025-45 新疆国际实业股份有限公司 关于董事、高级管理人员辞职暨补选董事、聘任高级管理人员的 公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或重大遗漏。 一、董事、高级管理人员辞职情况 新疆国际实业股份有限公司（以下简称"公司"）董事会于近日 收到沈永先生的书面辞职报告，沈永先生因工作调整的原因辞去公司 董事、董事会秘书及董事会专门委员会相关职务，其仍在公司继续担 任公司副总经理职务。辞职报告自送达公司董事会之日起生效。截至 本公告披露之日，沈永先生持有公司股份 7,900 股，沈永先生不存在 应当履行而未履行的承诺事项，其股份变动将严格遵守《深圳证券交 易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员 减持股份》《深圳证券交易所上市公司自律监管指引第 10 号——股 份变动管理》等法律法规及规范性文件的相关规定。 二、补选董事候选人的情况 董 事 会 个人简历： 公司于 2025 年 9 月 5 日召开第九届董事会第八次临时会议，审 议通过了《关于选举公司第九届董事会非独立董事的议案》。经公司 ...

Group 1 - The company, Huaxi Securities, will participate in the "2025 Online Collective Reception Day for Investors in Sichuan Region and Half-Year Report Performance Briefing" organized by the Sichuan Provincial Association of Listed Companies and Shenzhen Panorama Network Co., Ltd [1] - The event aims to enhance interaction and communication with investors regarding the company's performance for the fiscal year 2024 and the first half of 2025, corporate governance, development strategy, operational status, and sustainable development [1] - The company encourages investors to actively participate in the online event to discuss various topics of interest [1]

Group 1 - The company has received the drug registration certificate for Pirfenidone Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][2] - The drug is classified as a Class 4 chemical drug and is indicated for the treatment of partial seizures in adults and children aged 4 years and above [2] - The original developer of the drug is Eisai Europe Limited, which first launched it in the EU in July 2012, followed by approvals in the US and Japan [2] Group 2 - The sales amount for the original drug in 2024 is projected to be approximately 96.52 million yuan, reflecting a year-on-year growth of 39.74% [2] - The company has entered into a commercial cooperation agreement with Anhui Wanbang Pharmaceutical Technology Co., Ltd., where Wanbang will handle sales and promotion of the drug [2] - The company is responsible for the production and supply of the drug and will share in the profits from sales after the drug is launched [2]